|
In recent years pharmaceutical companies have increased research and development spending, however this has failed to generate many new drug approvals. Consequently companies are relying on the ability of screening methods and technologies to identify lead compounds with therapeutic capabilities. However, current screening efforts are proving one of industry’s most potent bottlenecks requiring further attention.
SMi’s 3rd Annual Advances in High Throughput Screening Conference aims to review and evaluate the latest developments in High Throughput Screening (HTS), with a particular focus on instrumentation, assay methodologies and HTS as a business opportunity. How can HTS systems be integrated into the business? How does a company select the most appropriate technology in the first place? Hear the latest from top pharmaceutical companies as they explain how to adopt the right strategies and right technology for your company. This event will also aim to explore some of the emerging trends in HTS, complete with an outlook on market drivers and shapers and future potential as part of the drug development process.
Gain an insight from key industry leaders in the field including:
Dr Fredric Vinick, Senior Vice President, Drug Discovery, Genzyme
Dr Jefferson Paslay, Vice President, Screening Sciences, Wyeth
Dr Mark Divers, Director, HTS Centre, AstraZeneca
Dr Gregory Kaczorowski, Senior Director, Department of Ion Channels, Merck Research Laboratories
Dr Lorenz Mayr, Technology Programme Head, Lead Discovery Center, Novartis
Dr Andreas Sewing, Head, Automated Screening Technologies, Pfizer
Dr Everard Pap, Head, Assay Technologies, Lead Discovery, Aventis
Dr Emanuel Lohrmann, Research Fellow, HTS, Bayer
Dr Christian Bergsdorf, Post Doctor, Assay Development, HTS, Schering
Programme highlights include:
HTS AS AN INTEGRAL PART OF THE EARLY DRUG DISCOVERY PROCESS: Analyse HTS operations and investments in HTS technologies
INDUSTRIALISATION AND AUTOMATION OF HTS ASSAY DEVELOPMENT: Hear about the bottlenecks of traditional assay development and the impact of automated assays on optimisation
UNMET REQUIREMENTS IN HTS: Explore the areas that utilise the HTS market and the industry responses to market opportunities
LEARN FROM MISTAKES: Investigate the previous HTS methods and the application of new processes
STRATEGIES TO DISCOVER ION CHANNEL DRUGS: Learn about VIPR based ion channels and other novel approaches
INDUSTRY EXPERTS: Network with influential experts from leading pharmaceutical companies and gain an insight into their experiences
|
Events Home Page
